AstraZeneca's cancer drug fails to meet main goal in COVID-19 study

Nov 12 (Reuters) - AstraZeneca PLC said on Thursday its cancer treatment, Calquence, failed to meet the main goal of a mid-stage trial, testing it in patients hospitalized with respiratory symptoms of COVID-19. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.